RapidArc在前列腺癌放疗中的应用  

The application of Rapid Arc for prostate cancer

作　　者：张先稳[1] 张西志[1] 花威[1] 汪步海[1] 陈婷婷[1] 李军[1] 

机构地区：[1]江苏省苏北人民医院放疗科,江苏扬州225001

出　　处：《现代肿瘤医学》2015年第17期2503-2505,共3页Journal of Modern Oncology

摘　　要：目的:探讨Rapid Arc在前列腺癌放疗中的适用性。方法:对6例前列腺癌患者设计双弧Rapid Arc计划,处方剂量为7600c Gy。用COMPASS系统验证剂量。利用剂量体积直方图分析临床靶区、危及器官OARs的各评价指标。结果:CTV的HI、CI分别为1.08±0.03、0.87±0.06,有较好的均匀性和适合度。PTV的HI、CI稍差。膀胱和直肠的V40仅为(18.98±4.82)%和(20.50±3.03)%,平均剂量也较低,在3000c Gy左右。股骨头D5%也在4000c Gy以内。COMPASS剂量验证所得CTV和PTV各指标差异在4%以内,危及器官评价指标差异在5%以内。等中心处绝对剂量准确率达(99.08±0.66)%,靶区和各危及器官的γ通过率达96%、98%以上。结论:Rapid Arc能够满足前列腺癌放疗的临床剂量学要求。Objective：To study the application suitability of RapidArc for prostate cancer. Methods：We design two arcs RapidArc plan for 6 patients. Prescription dose was 7600cGy. The COMPASS dose verification system was used to verify these plans. Target and organs at risk（ OAR）were evaluated with dose-volume histograms（ DVH）. Results：CTV had good HI,CI,separately was 1. 08 ± 0. 03,0. 87 ± 0. 06. PTV HI,CI slightly worse. The V40 of blad-der and rectum were（18. 98 ± 4. 82）%,（20. 50 ± 3. 03）%. The Dmean was low,at about 3000cGy. The femoral head D5% within 4000cGy. The COMPASS dose verification of CTV and PTV index difference was less than 4%. In addi-tion,organs at risk evaluation index difference was less than 5%. Center absolute dose accuracy was（99. 08 ± 0. 66）%. The gamma pass rates of target and OARs were more than 96%,98%. Conclusion：RapidArc could satisfy the clinical requirements of dose radiotherapy for prostate cancer.

关 键 词：前列腺癌 调强放射治疗 剂量体积直方图 

分 类 号：R737.25[医药卫生—肿瘤]